EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS

Gisella Guerrera, PhD, Serena Ruggieri, MD, Mario Picozza, PhD, Eleonora Piras, PhD, Francesca Gargano, PhD, Roberta Placido, PhD, Claudio Gasperini, MD, Marco Salvetti, MD, Maria Chiara Buscarinu, MD, Luca Battistini, MD, Giovanna Borsellino, MD, and Daniela F. Angelini, PhD

Neurol Neuroimmunol Neuroinflamm 2020;7:e876. doi:10.1212/NXI.0000000000000876

Abstract

Objective
Infection with Epstein-Barr virus (EBV) has been associated with clinical activity and risk of developing MS. The purpose of this study is to investigate the impact of glatiramer acetate (GA) therapy on EBV-specific immune responses and disease course.

Methods
We characterized EBV-specific CD8 T lymphocytes and B cells during disease-modifying treatments in 2 groups of patients with MS. We designed a 2-pronged approach consisting of a cross-sectional study (39 untreated patients, 38 patients who had undergone 12 months of GA treatment, and 48 healthy donors compatible for age and sex with the patients with MS) and a 12-month longitudinal study (35 patients treated with GA). CD8 EBV-specific T cells and B lymphocytes were studied using pentamers and multiparametric flow cytometry.

Results
We find that treatment with GA enhances viral recognition by inducing an increased number of circulating virus-specific CD8 T cells ($p = 0.0043$) and by relieving their features of exhaustion ($p = 0.0053$) and senescence ($p < 0.0001, p = 0.0001$). B cells, phenotypically and numerically tracked along the 1-year follow-up study, show a steady decrease in memory B-cell frequencies ($p = 0.025$), paralleled by an increase of the naive B subset.

Conclusion
GA therapy acts as a disease-modifying therapy restoring homeostasis in the immune system, including anti-EBV responses.
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that persists within B cells in a latency state. The infection is usually kept under control by EBV-specific CD8 T lymphocytes, and it has been suggested that the defective control of EBV by T lymphocytes plays a role in the pathogenesis of MS, a disease in which dysregulation of the immune system leads to demyelination in the CNS. EBV-infected B cells are also found in ectopic follicles in the meninges of patients with MS but not in other inflammatory neurologic diseases. However, pathogenic processes linking EBV infection and MS are still unclear.

During several chronic viral infections, virus-specific CD8 T cells become functionally exhausted. These cells are unable to mount their effector activities useful to defeat the infection. This functional impairment is associated with the expression of inhibitory receptors, which negatively regulate lymphocyte function.

We have previously shown that disease activity is closely linked to the number of circulating CD8 T cells recognizing either lytic or latent EBV antigens. In the present study, we expanded the pentamers’ panel used in the previous work, and we extended our investigations to provide a phenotypic and functional characterization of EBV-specific CD8 T cells.

Moreover, recent studies have revealed a substantial role for B cells in MS, which may also involve their interaction with T cells, rather than the sole production of antibodies. Thus, we broadened our study to include the characterization of B cells focusing on their expression of markers of differentiation and on their ability to interact with T cells.

Glatiramer acetate (GA) is a first-line therapeutic against the relapsing-remitting form of MS (RRMS) in which it acts by immunomodulatory mechanisms, which also touch T and B cells, interfering with the disease course. Here, we show that GA treatment revives antiviral T-cell responses and determines a shift in B-cell phenotypic distribution with an increase of naive and a reduction of memory cells.

**Methods**

**Ethics statement**
Peripheral blood samples were collected after obtaining written informed consent from the study participants, in accordance with the Helsinki Declaration. The study protocol was reviewed and approved by the local ethics committees of the recruitment centers, San Camillo-Forlanini Hospital and Sant’Andrea Hospital. Reference number: 2015-000922-12.

**Statistical analysis**
Statistical analyses for continuous variables were performed using the Student t test. All variables were inspected for normal distribution. p Value summaries of parametric variables were calculated with ordinary 1-way analysis of variance (ANOVA), and the Tukey post hoc test was used for multiple comparisons. Kruskal-Wallis followed by Dunn multiple comparison tests were used for nonparametric variables (GraphPad Prism, v6.2). Differences between categorical variables were evaluated by the

**Study population and sample preparation**
A total of 112 patients with a clinical diagnosis of RRMS established according to the McDonald’s criteria (McDonald, 2017) were included in this study. Among these, 38 were treated with GA at 20 mg for at least 1 year (range 1–5 years), and 39 were untreated patients (i.e., free of therapy the time of sampling for at least the previous 6 months). In addition, 35 patients with RRMS were monitored longitudinally for 1 year, and blood was drawn at 3 (T1), 6 (T2), and 12 (T3) months after initiation of GA therapy (40 mg), preceded by 6-month washout from any previous therapy. Patients’ characteristics are summarized in table 1. Patients were supervised, both clinically and radiologically with scheduled follow-up every 6 months for at least 1 year to define the state of remission of the disease (no evidence of disease activity [NEDA] patients). Among the 39 untreated patients, 8 patients had evidence of disease activity (EDA patients). EDA were defined both clinically and with MRI in 60% of patients, whereas the remaining 40% were assessed only clinically. The blood was always drawn immediately after ascertaining the clinical symptoms and before steroid treatment. The control group included 48 samples from healthy donors (HDs) matched for age and sex with patients.

**Haplotype characterization, pentamer, antibodies, and functional assays**
Haplotype characterization was performed as described in supplementary material (links.lww.com/NXI/A301). Phycoerythrin-conjugated Pro5 (MHC Class I Pentamers loaded with the immunodominant peptides listed in table e-1 (links.lww.com/NXI/A302) were used as described in supplementary material.

To define the phenotypic and functional properties of pentamer+ CD8 T cells and B cells, we used the antibodies listed in supplementary material (links.lww.com/NXI/A301).

The ProMix EBV Peptide Pool (ProImmune, Oxford, United Kingdom), consisting of the 26 peptides listed in table e-2 (links.lww.com/NXI/A303), was used in the functional assay described in supplementary material (links.lww.com/NXI/A301).

**Glossary**

ANOVA = analysis of variance; CMV = cytomegalovirus; EBV = Epstein-Barr virus; EDA = evidence of disease activity; GA = glatiramer acetate; HD = healthy donor; IFN = interferon; KLRG1 = killer cell lectin-like receptor G1; LAMP = lysosomal-associated membrane protein 1; NEDA = no evidence of disease activity; RRMS = relapsing-remitting MS.
Pearson $\chi^2$ test. Statistical significance was inferred for $p$ values less than 0.05.

**Data availability**
Deidentified data can be made available on request.

**Results**

**Prevalence and frequency of virus-specific CD8 T cells**

We studied CD8 T cells specific for immunodominant peptides deriving from latent and lytic phases of the viral EBV cycle and restricted by the MHC class I molecules expressed by donors of our cohort, as described in table e-3 (links.lww.com/NXI/A304). As a control, pentamers loaded with peptides derived from the human cytomegalovirus (CMV) pp65 and IE1 proteins were also used.

We initially investigated the prevalence of EBV-specific CD8$^+$ T-cell responses in our cohort (figure 1A), namely the proportion of individuals with positive pentamer staining specific for at least 1 EBV epitope.

Furthermore, to investigate on the possible correlation between anti-EBV immune response and disease exacerbations,
the cohort of untreated patients with RRMS was stratified based on disease activity (EDA and NEDA).

We find that untreated NEDA patients with RRMS are characterized by a lower prevalence in positivity for both EBV latent peptides ($p = 0.012$) and CMV peptides ($p = 0.0026$) compared with GA-treated patients, whereas this difference is not statistically significant in the response to proteins expressed during the lytic cycle of the virus. Compared with HDs, more GA-treated patients show detectable antiviral CD8 T cell–mediated recognition of all antigens tested, with a percentage of prevalence for EBV latent antigen significantly higher ($p = 0.004$). Although this part of the study is limited to cross-sectional measurements, we speculate that GA may improve immunologic reactivity to both EBV and CMV.

The frequency of virus-specific CD8 T cells in the peripheral blood was then compared between GA-treated and untreated patients with RRMS (figure 1B). In this set of analyses, only pentamer+ donors were evaluated. We confirmed that the frequency of CD8 T cells recognizing latent EBV antigens is not significantly different between both treated and untreated patients and HDs, whereas the frequency of CD8 T cells recognizing lytic antigens is higher in untreated EDA patients compared with HDs ($p = 0.012$). The frequency of EBV-specific CD8 T cells in GA-treated patients is also higher compared with that found in HDs and in untreated NEDA patients, but this difference does not reach statistical significance. Importantly, the frequency of CMV-specific CD8 T cells is comparable in GA-treated or untreated patients and in HDs. These results support the hypothesis that EBV reactivation, and the consequent expansion of CD8 T cells specific for EBV lytic antigens, may play a role in clinical relapses.

GA treatment restores normal features of EBV-specific CD8 T cells

PD-1 expression affects the functionality of antiviral T-cell responses and is upregulated by T cells in some chronic infectious diseases. We thus first measured the expression of PD-1 on pentamer+ CD8 T cells in patients with RRMS with or without therapy and in HDs (figure 2). We found that CD8 T cells specific for EBV latent antigens express higher PD-1 levels in untreated NEDA patients with MS compared with HDs ($p = 0.0042$ and $p = 0.0005$), suggesting that in untreated patients, these cells are at the limit of their functionality, with up to 80% of cells expressing PD-1. Treatment with GA seems to readjust the fraction of exhausted cells to the levels found in HD, although longitudinal analysis on the same patients would provide stronger support to this evidence. Although the number of patients in the EDA group was very low ($n = 3$), PD-1 expression on CD8 cells specific for lytic antigens is comparable to that found in healthy individuals (figure e-2, A and B, links lww.com/NXI/A300).
PD-1 expression in the general CD8 T-cell population was comparable in all groups (figure 2C). We next asked whether this exhausted phenotypic trait was mirrored by a dysfunctional response to EBV antigens. To address this issue, we measured in vitro the reactivity of CD8 T cells from HDs and untreated patients with MS to a pool of 26 immunodominant human leukocyte antigen-I-restricted EBV peptides. As read-outs, we measured intracellular production of interferon (IFN)-γ coupled with the measurement of degranulation (assessed by lysosomal-associated membrane protein 1 [LAMP-1] staining) and with the phenotypic characterization of EBV-responsive CD8 T cells (figure 3).

Peptide stimulation induced measurable production of IFNγ and exocytosis of lytic granules from all tested donors (figure 3, A and B). However, although the surface display of LAMP-1 between HDs and untreated patients with RRMS is comparable in the 2 groups (1.52% ± 0.8% vs 1.38% ± 0.3%), the latter show reduced production of IFN-γ compared with HDs (0.27% ± 0.19% vs 1.15% ± 1.02%; p = 0.0222), together with a reduced fraction of double-positive IFNγ+ LAMP+ CD8 T cells (0.76% ± 0.6% vs 0.13% ± 0.09%; p = 0.046). Thus, although in healthy individuals, direct cytotoxicity is strictly correlated with IFN-γ production, these 2 effector processes seem to be disjoined in MS.

IFNγ+ CD8 T cells were analyzed for the expression of CD127, CD45RA, and killer cell lectin-like receptor G1 (KLRG1) (figure 3C). The data show that the KLRG1+CD45RA−CD127− population, representing cytotoxic/terminally differentiated and senescent cells, is more represented in patients with RRMS compared with HDs (p = 0.0164).

We confirmed this finding also in the pentamer experimental setup, by showing that the senescent phenotype of EBV-reactive (i.e., IFNγ+) cells may be present also in nonactivated
We find that in untreated patients with RRMS, a significant fraction of CD8+ cells specific for both latent and lytic EBV antigens are CD127- KLRG1+, the phenotype that identifies senescent cells. This phenotype completely reversed in GA-treated patients (figure 4, B and C; p < 0.0001). This, together with the data on PD-1 expression, points to a possible positive effect of GA therapy on the anti-EBV T-cell response.

Phenotypic characterization of B cells during GA therapy

We next asked whether the therapy also modulates B cells, which are the direct targets of EBV and whose role in MS is underscored by the successful B cell–depleting therapeutic approaches; in addition, recent data in the literature suggest that this drug modulates B-cell function and activity. We monitored a group of patients before and after 3 (T1), 6 (T2), and 12 months (T3) of GA therapy. The absolute B-cell count shows no significant changes at all time points (data not shown). The ligand of PD-1, PD-L1, is equally expressed on B lymphocytes from patients before GA treatment and HD (figure 5A and figure e-2, links.lww.com/NXI/A300). However, treatment with GA gradually and significantly reduces PD-L1 expression on B lymphocytes after 6 months (T2) and 12 months (T3) of therapy (figure 5B; p = 0.0003). At the same time points, B-cell activation is also modulated: before treatment, a significantly higher fraction of B cells from patients express CD69 compared with HDs (figure 5C; p < 0.0001); after 3 and 6 months of GA therapy (p = 0.0087), however, there is a significant reduction of CD69 expression (figure 5D), particularly affecting the subsets of the memory and effector memory B cells (data not shown). We also noticed an increase in CD25 expression, which, however, does not reach statistical significance in any subpopulation of B cells (figure e-2), altogether indicating a lower level of activation of B cells during GA treatment.

We next asked whether GA directly modulates the expression of these receptors on preexisting cells or whether it induces modifications in the overall composition of B cells. To answer this question, we monitored the percentages of naive, memory, and effector B cells during therapy (figure 5, E–G, and figure 5H, I), and we measured the frequency of B cells expressing the proapoptotic molecule FAS/CD95 (figure 5, H and I, links.lww.com/NXI/A300). The results show that along with a decrease in PD-L1 and CD69 expression on B cells, there is also a strong decrease of memory B cells (figure 5F; p = 0.025), paralleled by a significant increase of effector memory B cells (figure 5G; p = 0.015). The naive B-cell subset, on the other hand, tends to increase during treatment with GA, but this increase does not reach statistical significance using ANOVA, whereas it results significant with a Student t test (figure 5E; T0 vs T2 p = 0.003; T0 vs T3 p = 0.0148). Moreover, the expression of FAS, which appears not to be modulated by GA therapy in total B cells (figure 5H), is upregulated on the memory B cell subset at 6 months (T2) (figure 5I; Student t test p = 0.0049) and decreases thereafter.
The longitudinal study of the B-cell phenotype in HDs and in untreated patients was not performed, unfortunately. This could have ruled out the possibility that the modulation of the receptors is due to time rather than to therapy; however, our finding that all these changes occur together after 6 months of therapy (T2) suggests that treatment with GA has an effect also on the B-cell compartment.

Discussion

EBV infection is usually kept in check by virus-specific lymphocytes, and here, we show that in patients with MS, these cells have features of exhaustion and are defective in their cytotoxic machinery. Thus, they may fail to effectively control EBV-infected autoreactive B cells, which might then accumulate in the CNS. Moreover, we show that GA, commonly used in the treatment of the disease, modulates antiviral immune responses, including the response against EBV infection, and we hypothesize that it favors the conditions for effective control of viral infection through a positive action on EBV-specific CD8 T cells. In GA-treated patients, these cells are found in over 60% of patients, and they show reduced levels of PD-1 and KLRG1 expression, indicating that the cellular effectors of the EBV-specific response are up and running. On the contrary, untreated patients are consistently the group with the lowest prevalence for antiviral positivity, and the positive patients have a significantly higher quota of antigen-specific T cells expressing markers of exhaustion (PD-1) or senescence (KLRG1) compared with both HDs and GA-treated patients.

All patients undergoing treatment with GA experienced disease stability, as evaluated both clinically and radiologically, supporting a role for effective EBV-specific T cells in the maintenance of immune homeostasis. In this study, we did not measure markers of EBV reactivation, but we and others have shown that CD8$^+$ EBV-specific T cells are present in active brain lesions of patients with MS, where antigens of the lytic activity are also detected. Thus, it is conceivable that during disease activity, EBV reactivation is taking place, finding a weakened and senescent antigen-specific T-cell population, which is unable to contrast the viral infection.
Functional data showed that EBV-specific T cells from untreated patients display signs of exhaustion and senescence, with low IFNγ production and reduced cytotoxic degranulation compared with healthy donors, whereas B cells on the contrary are significantly activated.

T-cell exhaustion has been shown to underlie T-cell dysfunction in chronic viral infections,\(^1\) including HIV.\(^2\) Exhausted virus-specific T cells show reduced proliferative potential and cytokine production, and this immunologic feebleness may favor viral persistence.\(^3\) In viral infection and tumors, a crucial marker that correlates with exhaustion is PD-1.\(^4\) We found a high expression of this marker on EBV-specific CD8 T cells and a concomitant high expression of its ligand, PD-L1, on B cells of untreated patients with RRMS. This state of immune breakdown, however, seems to be opposed by the action of GA because patients undergoing treatment show both a decrease in PD-1 expression levels on virus-specific CD8 T cells and a decrease in the expression of PD-L1 on B cells.

Lymphocytes’ senescence involves the reduced ability to respond to new antigens and in general to support an effective immune response.\(^5,6,7\) Immunosenescence is due to the general aging of the organism, to the overall history of antigenic exposure, to the infectious load, and above all to chronic or latent infections, which engage antigen-specific cells in a never-ending battle. Immunosenescent cells can be identified through the combined evaluation of the expression KLRG1, an inhibitory receptor expressed on natural killer cells and on terminally differentiated T lymphocytes, and CD127 (interleukin-7 receptor).\(^8\) We find that patients treated with GA show a clear decrease in the fraction of senescent EBV-specific CD8 T lymphocytes compared with untreated patients, suggesting that this treatment could revive or at least protect the antiviral immune response by reducing T-cell exhaustion.

Several studies in MS and in its animal model, experimental autoimmune encephalomyelitis, suggest that GA treatment is associated with an immunomodulatory effect acting broadly on cells of both the innate and adaptive immune system. For instance, GA therapy reduces the fraction of activated CD8\(^+\) T cells,\(^9\) remodels the composition of the B- and T-cell compartment, and influences cytokine secretion and immunoglobulin production following modulation of antigen-presenting cells’ functions.\(^10–14\) Our data show that after treatment, there are clear changes within the B-cell subset: naive B cells increase as opposed to memory B cells, and this occurrence is preceded by the expression on the FAS receptor on memory B cells. FAS is expressed by activated lymphocytes and induces apoptosis through activation-induced cell death. This process is thought to limit lymphocyte expansion and to eliminate anergic and autoreactive cells. Thus, the decreased frequency of potentially infected B cells, which continuously stimulate EBV-specific CD8 T lymphocytes, may affect also this cell compartment.

In conclusion, the results of the present study confirm that GA therapy acts as a disease-modifying therapy restoring homeostasis in the immune system, including anti-EBV responses. Suppression of inflammation is the most frequent mechanism of action of disease-modifying drugs in MS, but this can potentially lead also to unwanted suppression of antiviral immunity, which could then expose the patient to infection. Given the increased number of circulating virus-specific CD8 T cells and their decreased features of exhaustion and senescence, coupled with the increase of the fraction of naive B cells, it is possible that GA is safe also for use in patients with MS who have a proven viral infection.\(^25\)

**Study funding**

The work was partially supported by a grant from TEVA Italia s.r.l. (Teva 0211212014), from the Italian Ministry of Health (Progetto di ricerca Finalizzata RF-2018-12366111), and from the Italian Foundation for Multiple Sclerosis (FISM Progetto Speciale 2018/S/5) to L. Battistini.

**Disclosure**

G. Guerrera declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. S. Ruggieri has received fee as speaking honoraria from Teva, Merck Serono, and Biogen; travel grant from Biogen and Merck Serono; and fee as advisory board consultant from Merck Serono and Novartis. M. Piccozza, E. Piras, F. Gargano, and R. Placido declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. C. Gasperini has served on advisory boards and/or has received travel grants and/or speaker honoraria from Merck Serono, Roche, Teva Italia, Biogen, Almirall, Novartis, and Sanofi-Genzyme. M. Salvetti received research support and speaking honoraria from Biogen, Merck, Novartis, Roche, and Sanofi. M.C. Buscarini declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. L. Battistini received research support and speaking honoraria from Baxter, Merck, Novartis, Roche, and Sanofi. G. Borsellino and D.F. Angelini declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Go to Neurology.org/NN for full disclosures.

**Publication history**

Received by *Neurology: Neuroimmunology & Neuroinflammation* April 14, 2020. Accepted in final form July 8, 2020.

---

**Appendix Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gisella Guerrera</strong>, PhD</td>
<td>Neuroimmunology Unit, IRCSS Fondazione Santa Lucia, Rome, Italy</td>
<td>Major role in the acquisition and the analysis of data</td>
</tr>
<tr>
<td>Serena Ruggieri, MD</td>
<td>Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy; Neuroimmunology Unit, IRCSS Fondazione Santa Lucia, Rome, Italy</td>
<td>Recruited and followed patients</td>
</tr>
</tbody>
</table>


EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS

Gisella Guerrera, Serena Ruggieri, Mario Picozza, et al.

*Neurol Neuroimmunol Neuroinflamm* 2020;7;
DOI 10.1212/NXI.0000000000000876

This information is current as of August 17, 2020